Abstract

Objective: Identify gene expression profiles associated with OA processes in articular cartilage and determine pathways changing during the disease process.

Methods: Genome wide gene expression was determined in paired samples of OA affected and preserved cartilage of the same joint using microarray analysis for 33 patients of the RAAK study. Results were replicated in independent samples by RT-qPCR and immunohistochemistry. Profiles were analyzed with the online analysis tools DAVID and STRING to identify enrichment for specific pathways and protein-protein interactions.

Results: Among the 1717 genes that were significantly differently expressed between OA affected and preserved cartilage we found significant enrichment for genes involved in skeletal development (e.g. TNFRSF11B and FRZB). Also several inflammatory genes such as CD55, PTGES and TNFAIP6, previously identified in within-joint analyses as well as in analyses comparing preserved cartilage from OA affected joints versus healthy cartilage were among the top genes. Of note was the high up-regulation of NGF in OA cartilage. RT-qPCR confirmed differential expression for 18 out of 19 genes with expression changes of 2-fold or higher, and immunohistochemistry of selected genes showed a concordant change in protein expression. Most of these changes associated with OA severity (Mankin score) but were independent of joint-site or sex.

Conclusion: We provide further insights into the ongoing OA pathophysiological processes in cartilage, in particular into differences in macroscopically intact cartilage compared to OA affected cartilage, which seem relatively consistent and independent of sex or joint. We advocate that development of treatment could benefit by focusing on these similarities in gene expression changes and/or pathways.

Introduction

Osteoarthritis (OA) is a degenerative disease of the joints causing pain and disability for an increasing proportion of the population thereby imposing a large patient and socio-economic burden [1,2]. Risk factors for OA include age, sex, joint injury, obesity, and mechanical stresses. In addition, predisposition to OA has a considerable genetic component and it has been proposed that OA can be viewed as a continuum resulting from the interaction between genetics affecting cartilage extracellular matrix composition and joint shape and sensitivity to the other factors mentioned [3,4]. Major efforts are made to identify loci associated with OA susceptibility to elucidate underlying mechanisms [5]. Treatment options to slow down or reverse the OA process are still very limited and at the time of diagnosis the damage is already irreversible. Together, this emphasizes the importance to increase insight into the disease process and to identify genes and pathways involved in development of OA. A way to achieve this is by investigating the pathophysiological
processes in articular cartilage by means of gene expression analyses. Initially, expression profiles were established for cartilage from knee OA joints in comparison to healthy joints using only a limited number of genes [6]. More recently, exploratory genome wide expression profiling has been performed for the intact cartilage of hip and knee OA joints of patients undergoing joint replacement surgery compared to non-OA joints either derived from autopsies or from neck of femur fractures [7,8]. These studies showed that many genes involved in extracellular matrix (ECM) production as well as genes involved in ECM degradation or inflammation were changed. Together, this resulted in significant enrichment for genes involved in skeletal development and response to external stimuli. Although studies that compare healthy cartilage with the preserved cartilage of joints from OA patients are very useful to acquire insight into the pathogenetic differences, the findings are likely biased by confounding factors such as innate differences, age, and stratification by joint. Moreover, due to the study design distinction between age-related changes and early or late changes of OA pathophysiology is hampered.

One of the characteristics of OA is focal loss of articular cartilage, resulting in areas of degradation as well as areas with a relative preservation of cartilage thickness and appearance in the joint. Insight into gene expression specific for the focal areas of cartilage degradation compared to those in preserved areas can provide clues towards dynamic changes of genes and pathways involved in OA pathophysiology independent of confounding factors such as age. Gene expression profiles of cartilage from OA affected and macroscopically preserved areas of the same joint have been determined before, however, in most of these studies limited numbers of donors (4–5 knee joints) were included [9–11].

As part of the ongoing Research Arthritis and Articular Cartilage (RAAK) study we set out to perform genome wide analysis of differential gene expression by comparing 33 pairs of matched OA affected and preserved cartilage samples, originating from the same joint of patients that underwent total joint replacement of either hip or knee. Results provide further insights in the ongoing OA disease processes in cartilage, in particular into differences in macroscopically intact cartilage compared to OA affected cartilage.

Materials and Methods

Ethics statement

Participants of the RAAK study provided written informed consent. The ongoing RAAK study and its consent procedure is approved by the institutional ethics review committee (Commissie Medische Ethiek of the Leiden University Medical Center; protocol no. P08.239).

Discovery cohort

The RAAK study is aimed at the biobanking of joint materials as well as mesenchymal stem cells and primary chondrocytes from patients and controls in the Leiden University Medical Center and collaborating outpatient clinics in the Leiden area. In the current study we used paired preserved and OA affected cartilage samples for 33 donors undergoing joint replacement surgery for primary OA (22 hips, 11 knees). Characteristics of the donors are shown in Table S1.

At the moment of collection (within 2 hours following surgery) tissue was washed extensively with phosphate buffered saline (PBS) to decrease the risk of contamination by blood. Cartilage was classified macroscopically and collected separately from OA affected and preserved regions around the weight-bearing area of the joint (Figure S1). Classification was done based on predefined features of OA related damage as described previously [9,10]: color/whiteness of the cartilage, surface integrity as determined by visible fibrillation/crack formation, and depth and hardness of the cartilage upon sampling with a scalpel. Care was taken to avoid contamination with bone or synovium. Collected cartilage was snap frozen in liquid nitrogen and stored at −80°C prior to RNA extraction.

Validation and replication cohort

Validation was performed by RT-qPCR in 8 sample pairs of the discovery cohort (3 knee and 5 hip) and for replication of the results we included 28 additional matched sample pairs (20 knee, 8 hip) of similar mean age (shown in Table S1). Sampling procedures were according to the discovery cohort.

RNA isolation

Cartilage samples were pulverized using a Retsch MM200 under cryogenic conditions. On average 150 mg of pulverized cartilage was dissolved in 1 ml of Trizol reagent, and mixed vigorously. After addition of 200 µl of chloroform the sample was mixed and centrifuged for 15 minutes (16,000 g). The clear aqueous layer was transferred to a new vial and 1 volume of 70% ethanol/DEPC-treated water was added to precipitate RNA. RNA was collected using Qiagen mini columns according to the manufacturers protocol and quality was assessed using a Bioanalyzer lab-on-a-chip. RNA integrity numbers above 8 were considered suitable for microarray analysis.

Microarrays

After in vitro transcription, amplification, and labeling with biotin-labeled nucleotides (Illumina TotalPrep RNA Amplification Kit) Illumina HumanHT-12 v3 microarrays were hybridized. Sample pairs were randomly dispersed over the microarrays, however each pair was measured on a single chip. Microarrays were read using an Illumina Beadarray 500GX scanner and after basic quality checks using Beadstudio software data were analyzed in R statistical programming language. Intensity values were normalized using the “rsn” option in the Lumi-package and absence of large scale between-chip effects was confirmed using the Globaltest-package in which the individual chip numbers were tested for association to the raw data [12]. After removal of probes that were not reliably detected (detection P>0.05 in more than 50% of the samples) a paired t-test was performed for the remaining 13277 probes comprising 11421 unique genes on all sample pairs while adjusting for chip (to adjust for possible batch effects) and using multiple testing correction as implemented in the “BH” (Benjamini and Hochberg) option in the Limma-package. Analyses for differential expression between OA and healthy and between preserved and healthy cartilage was performed likewise, adjusting in addition for sex and for age.

Gene expression profiles of the samples have been deposited in NCBI’s Gene Expression Omnibus [13] and are accessible through GEO Series accession number GSE57218.

Quantitative reverse transcription PCR (RT-qPCR)

0.5 µg of total RNA was processed with the First Strand cDNA Synthesis Kit according to the manufacturer’s protocol (Roche Applied Science) and RT-qPCR was performed for the 19 genes showing at least 2-fold expression differences in the microarray analysis (Taqman gene expression assays used are listed in Table S2) using the Biomark 96.96 Dynamic Arrays Fluidigm RT-qPCR platform [14]. Relative gene expressions were calculated with the
Differential expression between preserved and OA affected cartilage

To identify genes with changed expression in response to ongoing OA processes genome wide expression profiles were generated for preserved and OA affected cartilage of the same joint of 33 donors. Characteristics of the donors are shown in Table S1. Males (N=13) and females (N=20) included in the study were aged between 54 and 80 years (mean age: 66.2). In total, 22 patients received a hip replacement and 11 patients underwent total knee replacement. Among all OA joints included in this study (61 in total), 28 pairs were randomly selected to assess the Mankin scores of preserved and affected areas. Mankin scores were significantly higher in the samples macroscopically designated as ‘OA affected’ as compared to sections distinguished as ‘preserved’ (mean Mankin score 7.8 vs. 4.7, respectively, \(P=4\times10^{-4}\), paired t-test) and as a result gene expression differences can be directly linked to these differences in Mankin scores.

After normalization and correction for multiple testing, significant differential expression between the OA affected and preserved cartilage was identified for 1883 probes, representing 1717 unique genes (Table S3). Among the 1717 unique genes 19 were differently expressed with fold-changes of 2 and higher (Table 1). Notably, 14 of these were up-regulated in OA as compared to preserved cartilage and only 5 were down-regulated. Overall, 748 (41%) of the differentially expressed genes were up-regulated. Larger fold changes were observed in expression of genes well known for their association with OA cartilage such as tumor necrosis factor alpha-induced protein 6 (TNFAIP6) also known as TSG-6, 2.9-fold up in OA cartilage; \(P=4.4\times10^{-10}\), cytokine receptor-like factor 1 (CRLF1), 3-fold up in OA cartilage; \(P=4.4\times10^{-8}\), and Wnt-inhibitor frizzled related protein beta (FRzb), 2.5-fold down in OA cartilage; \(P=1.3\times10^{-5}\). A notable gene highly up-regulated in OA cartilage was neuronal growth factor (NGF), 2.3-fold up; \(P=3.4\times10^{-7}\).

Validation of the 19 genes with fold-changes of 2 or higher in 8 sample pairs used in the microarray analyses by means of RT-qPCR showed similar effect sizes and directions as those found in the microarray analysis (Table S5). Replication performed in an additional set of 28 independent preserved and affected cartilage sample pairs also showed comparable effect sizes and directions and, except for cysteine-rich secretory protein LCCL domain-containing 1 precursor (CRISPLD1), all genes were significantly different expressed (Table 1). Individual expression boxplots of the replicated genes are shown in Figure S2.

Expression profiles of genes with fold-changes of 2 and higher were analyzed for association with Mankin score as a grade of disease severity (Table 2). Almost all genes associated with Mankin score, except for COL9A1, HBA2 and HBB. To further characterize expression of the 19 genes with highest fold changes in OA affected cartilage, we investigated whether the observed changes were either joint or sex specific. As shown in Table 2, for most of the genes fold changes of the (joint or sex) stratified analyses were highly comparable and not statistically different from those of the discovery analysis. However, increased expression of pregnancy-associated plasma protein A (PAPPA) was significantly less pronounced in knee OA (1.3-fold increase) than in hip OA (2.6-fold increase).

In addition to the gene expression profiles of preserved and OA affected cartilage, gene expression profiles were also generated for 7 healthy cartilage (characteristics of the donors are shown in Table S1) and explored for the 19 genes. For most of these 19 genes we did not find significant differences between healthy and preserved cartilage. However, when analyzing the trend of the differences between healthy, preserved and OA affected cartilage we did find a significant linear effect on the expression of most genes. In contrast, expression changes of CRISPLD1 and COL9A1 in healthy versus preserved cartilage were not significant and appeared to be increased while the expression in preserved versus OA affected cartilage was found to be decreased (Figure S3).

Functional annotation of genes differently expressed in OA affected cartilage

To investigate whether the genes differently expressed between preserved and OA affected cartilage belonged to specific pathways, we used the online functional annotation tool DAVID. Seven GO-terms referring to 6 independent pathways were identified

2-\(\Delta\Delta\text{Ct}\) method [15], using household gene Beta Actin (ACTB) expression as internal standard.

Immunohistochemistry and staining analysis

For histological examination, joints were fixed using a 4% formaldehyde solution. Subsequently, samples were decalcified using a 10% EDTA solution and embedded in paraffin. Sections (5 \(\mu\)m) adjacent to the collected area were stained using hematoxilin and eosin (H&E) and toluidine blue. Immunohistochemistry was performed for SERPINE1 (mouse monoclonal antibody from American Diagnostica Inc.) without antigen retrieval and for CD55 (rabbit polyclonal antibody from Santa Cruz Biotechnology Inc.) with heat antigen retrieval (0.01 M Citratebuffer pH = 6.0) as described previously [16].

Quantification of OA related cartilage damage was scored by 2 observers (JVMGB and YFMR) according to Mankin et al [17]. Quantification of SERPINE1 expression was performed by scoring staining of chondrocytes in the superficial, middle, and deep cartilage layer with a score of 0 (no staining), 1 (moderate staining), or 2 (strong staining). Using Generalized Estimating Equations, scores were summed and used as a predictor variable with Mankin score as outcome whilst correcting for sex and age of each donor.

Pathway analysis and protein-protein interaction

Gene enrichment among the 1717 genes showing significant differential expression was performed with the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool [18] selecting for biological processes identified in the Gene Ontology database (GOTERM_BP_FAT in the options menu implemented in DAVID), selecting for cell compartment (GOTERM_CC_FAT), or selecting for molecular function (GOTERM_MF_FAT) and using the microarray background (Hu- manHT-12_V3_0_R2_11283641_A). Pathways with \(P\leq0.05\) after correction for multiple testing according to Bonferroni were considered significant (Bonferroni corrections were performed by multiplying the raw \(P\)-values with the number of genes included in the analysis).

Enrichment in protein-protein interactions among the significant genes was analyzed with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 9.0 [19] available online.

Literature based candidate genes

Based on selected publications of genome wide association study meta-analyses [20–29] we investigated our expression dataset for evidence of differential gene expression of the reported significant candidate genes.

Results

Differential expression between preserved and OA affected cartilage

...
Table 1. Genes significantly differently expressed in OA affected cartilage.

| Gene symbol | Function              | Discovery | Replication |
|-------------|-----------------------|-----------|-------------|
|             | FC   | Dir. | Pval     | FC     | Dir. | Pval     |
| TNFAIP6     | cartilage development | 2.90 Up | 4.40 x 10^-8 | 4.01 Up | 3.61 x 10^-4 |
| CRLF1       | immune response       | 2.97 Up | 4.40 x 10^-8 | 4.01 Up | 8.09 x 10^-8 |
| LEPREL1     | cartilage development | 2.37 Up | 4.40 x 10^-8 | 2.88 Up | 9.49 x 10^-4 |
| CD55        | complement cascade    | 2.39 Up | 4.40 x 10^-8 | 0.00 Up | 5.18 x 10^-5 |
| RARRES2     | immune response       | 2.26 Down | 6.06 x 10^-8 | 3.32 Down | 1.23 x 10^-4 |
| NGF         | neurogenesis          | 2.16 Up | 3.36 x 10^-7 | 4.54 Up | 2.50 x 10^-5 |
| FRZB        | bone development      | 2.54 Down | 1.28 x 10^-6 | 3.04 Down | 4.39 x 10^-4 |
| SEPRN1       | complement cascade    | 2.40 Up | 1.30 x 10^-6 | 3.13 Up | 1.54 x 10^-4 |
| PTGES       | immune response       | 2.34 Up | 1.46 x 10^-6 | 3.29 Up | 1.76 x 10^-5 |
| SPP1        | ECM-receptor interaction | 2.53 Up | 3.40 x 10^-8 | 2.56 Up | 7.05 x 10^-3 |
| CXCL14      | immune response       | 2.16 Up | 3.54 x 10^-6 | 4.97 Up | 1.01 x 10^-4 |
| TNFRSF11B   | bone development      | 2.10 Up | 4.23 x 10^-6 | 2.69 Up | 6.58 x 10^-4 |
| FNI         | ECM-receptor interaction | 2.31 Up | 1.13 x 10^-5 | 1.52 Up | 3.28 x 10^-2 |
| HBA2        | oxygen transport      | 2.26 Up | 2.02 x 10^-5 | 2.97 Up | 6.15 x 10^-3 |
| HBB         | oxygen transport      | 2.00 Up | 6.97 x 10^-5 | 2.50 Up | 1.69 x 10^-2 |
| PAPPA       | wound healing         | 2.08 Up | 7.69 x 10^-5 | 2.25 Up | 4.05 x 10^-3 |
| CRISPLD1    | –                     | 2.50 Down | 1.42 x 10^-4 | 1.05 – | 7.54 x 10^-3 |
| COL9A1      | cartilage development | 2.18 Down | 2.67 x 10^-4 | 3.14 Down | 2.27 x 10^-4 |
| CHRDL2      | cartilage development | 2.39 Down | 3.55 x 10^-4 | 5.33 Down | 5.71 x 10^-4 |

Shown are results of the microarray analysis (Discovery) and the replication for genes with at least 2-fold change (Dir.: direction of effects relative to OA; FC: fold change; Pval: P-value).
doi:10.1371/journal.pone.0103056.t001
### Table 2. Characteristics of the replicated genes.

| Gene symbol | Hip pVal | FC | Knee pVal | FC | Male pVal | FC | Female pVal | FC |
|-------------|----------|----|-----------|----|-----------|----|-------------|----|
| TNFAIP6     | 1.E-05   | 2.80 | 3.89E-05  | 3.10 | 6.19E-03  | 3.09 | 7.88E-04  | 2.78 |
| CRLF1       | 3.E-07   | 2.93 | 1.49E-04  | 3.06 | 1.47E-03  | 3.51 | 1.22E-03  | 2.67 |
| LEPREL1     | 5.E-15   | 2.50 | 3.85E-05  | 2.12 | 1.67E-02  | 2.90 | 7.88E-04  | 2.07 |
| CD55        | 8.E-11   | 2.67 | 3.85E-05  | 1.92 | 6.86E-03  | 2.63 | 1.53E-03  | 2.25 |
| RARRES2     | 6.E-08   | 0.42 | 3.85E-05  | 0.48 | 3.18E-02  | 0.44 | 5.51E-03  | 0.44 |
| NGF         | 2.E-09   | 2.39 | 1.49E-04  | 2.03 | 7.26E-03  | 2.68 | 5.48E-03  | 2.02 |
| FRZB        | 1.E-05   | 0.35 | 1.30E-04  | 0.50 | 3.67E-02  | 0.36 | 3.20E-03  | 0.41 |
| SERPNE1     | 1.E-03   | 2.40 | 6.10E-04  | 2.41 | 6.19E-03  | 2.64 | 8.36E-03  | 2.26 |
| PTGES       | 5.E-05   | 2.40 | 3.54E-04  | 2.21 | 1.70E-02  | 2.81 | 5.05E-03  | 2.07 |
| SPP1        | 3.E-05   | 2.56 | 1.94E-04  | 2.46 | 5.87E-02  | 2.64 | 9.09E-03  | 2.45 |
| CXCL14      | 2.E-04   | 2.49 | 1.87E-04  | 1.63 | 3.16E-02  | 2.73 | 9.09E-03  | 1.85 |
| TNFRSF11B   | 1.E-05   | 2.27 | 1.87E-04  | 1.80 | 8.65E-02  | 2.63 | 8.36E-03  | 1.82 |
| FNI         | 9.E-05   | 2.64 | 1.49E-04  | 1.83 | 1.40E-01  | 2.89 | 9.35E-03  | 2.00 |
| HBA2        | 1.E-01   | 2.46 | 1.01E-03  | 1.91 | 5.04E-02  | 1.96 | 2.46E-02  | 2.49 |
| HBB         | 2.E-01   | 2.17 | 1.50E-03  | 1.70 | 1.30E-01  | 1.72 | 2.86E-02  | 2.21 |
| PAPPA       | 2.E-05   | 2.59 | 4.68E-04  | 1.34 | 1.98E-01  | 2.22 | 4.79E-02  | 1.99 |
| CRISPLD1    | 6.E-02   | 0.38 | 5.98E-03  | 0.44 | 4.28E-02  | 0.36 | 2.56E-03  | 0.43 |
| COL9A1      | 6.E-01   | 0.42 | 6.24E-03  | 0.54 | 6.46E-02  | 0.42 | 4.95E-03  | 0.49 |
| CHRLD2      | 3.E-04   | 0.37 | 3.56E-03  | 0.52 | 2.09E-01  | 0.34 | 2.70E-02  | 0.48 |

Results of the analysis for association of the genes with Mankin score and for joint- and sex-stratified analyses.
doi:10.1371/journal.pone.0103056.t002
The most significant GO-term was observed for “skeletal system development.” This term captured several of the genes with fold-changes of 2 or higher (e.g. \( \text{FRZB} \) and \( \text{TNFRSF11B} \)). Furthermore, of note was the GO-term referring to “extracellular matrix organization” including decorin (DCN) and several collagens (e.g. \( \text{COL1A2} \), \( \text{COL2A1} \), \( \text{COL3A1} \)). When analyzing for enrichment using the cellular compartment option, most significant GO-term was “extracellular matrix,” and analyzing for molecular function showed genes involved in “copper ion binding” and “glycosaminoglycan binding” to be significantly enriched (Table 3).

Among the 19 genes that were highly changed in OA affected cartilage (at least 2-fold), 3 pathways were significantly enriched with lowest P-value for GO-term “response to wounding” (Table 4), which included the genes \( \text{TNFAIP6} \), \( \text{SERPINE2} \), and \( \text{CD55} \). When analyzing for interaction among proteins encoded by these genes using STRING, we found significant enrichment for protein-protein interactions (\( P = 4.7 \times 10^{-10} \)), in which fibronectin-1 (\( \text{FN1} \)) seemed to play a central role considering that 6 of the 19 proteins were found to relate to \( \text{FN1} \) (Figure 1).

**Immunohistochemical assessment of proteins encoded by genes identified in the microarray analysis**

In addition to differential expression of proteins encoded by genes found in the microarray analysis, immunohistochemical (IHC) staining provides insight in expression pattern and localization of differentially expressed genes in the different cartilage layers. Therefore, as a proof of principal, IHC was performed for \( \text{SERPINE1} \) and \( \text{CD55} \). Figure 2 shows representative sections for the staining of preserved (\( P \)) versus OA affected cartilage, with Figure 2A and B showing an example of the H&E and Toluidine blue staining respectively (upper panel: 4x magnification, lower panel 20x magnification).

Immunohistochemistry for \( \text{SERPINE1} \) showed that the protein is expressed in chondrocytes and differential expression between OA and preserved cartilage at the protein level was very pronounced (Figure 2C). In OA affected cartilage, \( \text{SERPINE1} \) was not only expressed in the superficial layer, but also in the middle layer. In the most affected parts, we even observed \( \text{SERPINE1} \) protein expression in chondrocytes residing in the deep zone. In addition, increasing matrix staining of \( \text{SERPINE1} \) was observed with increasing OA affection state. We performed a quantification of the staining as described in Materials and Methods, and statistical analysis showed a significant difference between protein abundance in OA and preserved cartilage (\( P = 2.4 \times 10^{-5} \)). The expression difference seemed to correlate mostly with toluidine blue staining, and thus with the level of proteoglycan constituents of chondromucin aggregates in the samples (\( P = 9.9 \times 10^{-6} \)).

\( \text{CD55} \) protein expression was most pronounced in the superficial layer, with higher levels in the more OA affected zones of the cartilage, while hardly any \( \text{CD55} \) positive cells were detected in the deep layer (Figure 2D). The differences, however, were more subtle than for \( \text{SERPINE1} \) and the range in the quantification did not allow for statistical analysis.

**Prioritization of genes residing in compelling genome wide association signals**

In order to explore whether genes identified by genome wide association studies are active in cartilage and/or change in response to the OA process, we screened for differential expression of genes originating from recently published large scale meta analyses on OA (Table 5). Sixteen of the 29 genes selected were well detected in the microarray (\( P_{\text{detected}} < 0.05 \)) and from these, 8 were significantly different between OA and preserved cartilage. Most genes showed only modest expression changes. Of note was differential expression of the HMG-box transcription factor 1 (\( \text{HBP1} \)) gene, identified in the Rotterdam study [24], which showed 1.1-fold up-regulation in OA cartilage (\( P = 2.0 \times 10^{-7} \)).

**Discussion**

As part of the RAAK study we compared genome wide expression levels between preserved and OA affected cartilage of the same joint from 33 donors. Such a paired study design allows the detection of genes specifically involved in the OA pathophysiological process, independent of inter-individual or age-related confounding factors as also reflected by the highly comparable differential gene expression patterns when stratifying according to joint and sex. After correction for multiple testing 1717 unique genes showed significant differential expression, of which 19 genes had a fold-change of 2 or higher. In an independent paired cartilage sample set, differential expression was confirmed for 18 genes by RT-qPCR. For most of these genes, except \( \text{HBB2} \), \( \text{HBB} \), and \( \text{COL9A1} \), expression associated with disease severity as determined by scoring according to Mankin [17], and OA-associated increase in protein expression for 2 genes (\( \text{CD55} \) and \( \text{SERPINE1} \)) was demonstrated by immunohistochemistry.

We confirmed several genes previously identified in within-joint analyses for OA affected versus preserved cartilage as well as analyses comparing preserved cartilage from OA affected joints versus healthy cartilage such as the inflammatory genes \( \text{CD55} \) [8], \( \text{PTGES} \) and \( \text{TNFAIP6} \) [11]. This overlap is noteworthy since in our analysis considerably more samples were included. A large sample size increases power to detect replicable findings and allows detection of differences that were previously missed or more subtle. Our data thus indicate that at least a number of genes are consistently involved in the OA disease process despite the appreciated heterogeneous pathophysiology. Another gene present among the top genes and highly up-regulated in OA affected cartilage was the tumor necrosis factor receptor superfamily 11b (\( \text{TNFRSF11B} \)) gene encoding osteoprotegerin. Very recently we reported in this protein on a gain of function mutation likely causal in a family with early onset OA with chondrocalcinosis [30]. In this respect, the up-regulated expression, could contribute to respective mineralization of the cartilage and eventually formation of bone, a major hallmark of the ongoing osteoarthritis disease process.

Studies comparing intact cartilage with OA affected cartilage of the same joint allow detection of gene expression changes specific to the ongoing OA pathophysiological processes independent of confounding factors such as sex and age and joint as was also demonstrated by the highly comparable results of our stratified analysis. Identification of such genes commonly changing during OA independent of joint site or sex could be very useful with respect to drug development. On the other hand, differences identified between the intact cartilage derived from patients undergoing joint replacement surgery and healthy cartilage of independent joints are of a cross-sectional nature and provide information on innate differences among OA patients as well as genes changing during OA. Therefore, genes overlapping among the different studies may be of interest to better understand dynamic changes during onset and ongoing OA. A notable example was the expression of the \( \text{COL9A1} \) gene that was higher in preserved as compared to healthy cartilage (3.6-fold), but was subsequently decreased in the OA affected cartilage (Figure S3).
| Analysis option: GO-Term | Count | Pct. | Enr. | Pval  | Pval_adj | FDR  |
|-------------------------|-------|------|------|-------|----------|------|
| Biological Processes GO:0001501 — skeletal system development | 59    | 3.86 | 2.12 | 5.21×10⁻⁸ | 7.97×10⁻⁵ | 9.53×10⁻⁵ |
| Biological Processes GO:0007167 — enzyme linked receptor protein signaling pathway | 56    | 3.66 | 1.88 | 5.74×10⁻⁶ | 8.78×10⁻³ | 1.05×10⁻² |
| Biological Processes GO:0008285 — negative regulation of cell proliferation | 57    | 3.73 | 1.81 | 1.52×10⁻⁵ | 2.32×10⁻² | 2.77×10⁻² |
| Biological Processes GO:0005996 — monosaccharide metabolic process | 40    | 2.61 | 2.07 | 1.64×10⁻⁵ | 2.51×10⁻² | 3.00×10⁻² |
| Biological Processes GO:0030198 — extracellular matrix organization | 24    | 1.57 | 2.67 | 2.10×10⁻⁵ | 3.22×10⁻² | 3.85×10⁻² |
| Biological Processes GO:007155 — cell adhesion | 93    | 6.08 | 1.53 | 3.30×10⁻⁵ | 4.76×10⁻² | 5.69×10⁻² |
| Biological Processes GO:0022610 — biological adhesion | 93    | 6.08 | 1.53 | 3.30×10⁻⁵ | 5.06×10⁻² | 6.04×10⁻² |
| Cellular Compartment GO:0031012 — extracellular matrix | 69    | 4.51 | 2.26 | 1.49×10⁻¹ | 2.29E-07 | 2.19E-07 |
| Cellular Compartment GO:0005578 — proteinaceous extracellular matrix | 65    | 4.25 | 2.03 | 2.63E-10 | 4.02E-07 | 3.86E-07 |
| Cellular Compartment GO:0044421 — extracellular region part | 133   | 8.69 | 1.56 | 1.10E-07 | 1.68E-04 | 1.61E-04 |
| Cellular Compartment GO:0044420 — extracellular matrix part | 30    | 1.96 | 2.90 | 2.16E-07 | 3.31E-04 | 3.17E-04 |
| Cellular Compartment GO:0005581 — collagen | 14    | 0.92 | 4.45 | 5.20E-06 | 7.95E-03 | 7.62E-03 |
| Molecular Function GO:003507 — copper ion binding | 19    | 1.24 | 3.36 | 6.69E-06 | 1.02E-02 | 1.08E-02 |
| Molecular Function GO:0005539 — glycosaminoglycan binding | 29    | 1.90 | 2.40 | 1.99E-05 | 3.04E-02 | 3.20E-02 |
| Molecular Function GO:0005198 — structural molecule activity | 84    | 5.49 | 1.58 | 2.52E-05 | 3.85E-02 | 4.06E-02 |

Analysis considering the biological processes option in DAVID (GOTERM_BP_FAT), the cellular compartment option (GOTERM_CC_FAT), or the molecular function option (GOTERM_MF_FAT) as indicated in the first column, using medium classification stringency for all genes significantly differently expressed between OA affected and preserved cartilage (GO-Term: GO-terms within the different clusters; Count: number of genes identified for the respective GO-term; Pct: percentage of genes from total number of genes tested; Enr.: fold enrichment of indicated pathway; Pval: P-value; Pval_adj: adjusted P-value; FDR: false discovery rate).
Although we acknowledge the fact that the included 7 healthy cartilage samples had a large age-range, our results are in line with the findings of Karlsson et al [8] and Xu et al [7] showing increased expression of COL9A1 in cartilage from patients undergoing joint replacement surgery in comparison to healthy cartilage. This altered direction of effect in ongoing OA may explain the fact that COL9A1 was found not to be associated with Mankin score and suggests that it is mainly involved in the initial response of the chondrocyte to cartilage damage. Gene enrichment analyses performed with all significant genes showed especially that genes involved in the skeletal development were changed in OA affected as compared to preserved cartilage. Notably, this is in accordance with observations from Xu et al [7] who found enrichment of genes involved in skeletal development by comparing healthy cartilage versus cartilage of OA affected joints, suggesting that this is a pathway commonly affected in OA cartilage, both in the initiation phases as well as in ongoing OA. The fact that genes involved in skeletal development (e.g. FRZB and TNFRSF11B, but also OSTF1, FGFR3, and IGFBP3; Table S3) change during ongoing OA processes confirms the hypothesis that OA chondrocytes lose their maturation arrested phenotype, specific for articular cartilage, towards their end-stage differentiation, resembling growth plate during skeletal development [3].

As reviewed by Barter and Young [31], gene expression differences in OA affected tissues may originate from changes in epigenetic control mechanisms. More recently, a comparison between the methylome of hip OA cartilage with cartilage of non-OA hips indeed showed more than 5000 differentially methylated loci whereas the annotated genes were mainly involved in pathways related to skeletal development [32] similar to the current and previous transcriptomic analyses [7]. Although direct association between such changes in DNA methylation and respective gene expression remains to be demonstrated, the skeletal developmental processes appear to consistently mark ongoing OA pathophysiology.

Recently, a GWAS for hand OA identified a locus in the aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) gene [33]. Expression of ALDH1A2 was shown to be allele dependent and with decreased expression in OA affected cartilage. Despite this and other recent successes of genome wide association studies [24,28] a variety of the identified signals indicate chromosomal regions without obvious OA candidate genes or regions of high linkage disequilibrium with many relative unknown genes [24,28].

### Table 4. Gene enrichment analysis.

| Term                                  | Count | Pct  | Enr. | Pval     | Pvaladj | FDR   |
|---------------------------------------|-------|------|------|----------|----------|-------|
| GO:0009611~response to wounding       | 6     | 31.58| 8.87 | 2.96E-04 | 5.63E-03 | 3.94E-01 |
| GO:0001501~skeletal system development | 5     | 26.32| 12.10| 4.95E-04 | 9.40E-03 | 6.58E-01 |
| GO:0006954~inflammatory response      | 5     | 26.32| 12.06| 5.01E-04 | 9.51E-03 | 6.65E-01 |

Pathway analysis considering the biological processes option in DAVID (GOTERM_BP_FAT) using the genes from Table 1 with at least 2-fold expression difference between OA affected and preserved cartilage (GO-Term: GO-terms within the different clusters; Count: number of genes identified for the respective GO-term; Pct: percentage of genes from total number of genes tested; Enr.: fold enrichment of indicated pathway; Pval: P-value; Pvaladj: adjusted P-value; FDR: false discovery rate).

Figure 1. Protein-protein interaction between the genes with expression changes of at least 2-fold (Table 1) as determined with STRING.

doi:10.1371/journal.pone.0103056.g001
Here, we provide a means of exploring the overall expression and behavior during disease in cartilage. Although OA should be considered a ‘whole joint disease’ [2] and expression profiles of other OA affected joint tissues such as those performed recently in subchondral bone [34] are highly valuable, expression profiles in OA cartilage could serve as one of the selection criteria to prioritize genes for functional follow-up studies and research directed at understanding pathophysiological mechanisms of OA and drug design. In our cartilage dataset, we found differential expression for several of the genes, among which \textit{PAPPA} was most significant (\( P = 1.1 \times 10^{-26} \)), positionally localized in close neighborhood of one the arcOGEN genome wide hits: rs4836732 within the \textit{ASTN2} gene. The exact linkage disequilibrium across this locus needs to be further explored. We also found \textit{HBPI}, at the chr7q22 locus, to be differentially expressed, although with small effect size in the OA versus preserved comparison (1.1-fold higher in OA affected cartilage). When comparing diseased cartilage (OA affected as well as macroscopically intact cartilage) with healthy cartilage we observed a much stronger and opposite direction of effects: healthy versus OA and healthy versus preserved both showed 1.4-fold lower expression (Table S4) in accordance with a previous study by Raine \textit{et al.} showing increased expression of \textit{HBPI} in OA affected cartilage [35]. Given that \textit{HBPI} resides in the 7q22 gene cluster [24] results mark this gene as most likely candidate for further functional follow-up investigations.

Although \textit{MCF2L} (MCF.2 cell line derived transforming sequence-like), a gene previously identified in GWA as an OA susceptibility gene [22], was not well-detected in the microarray analysis, the significant increased expression of neuronal growth factor (\textit{NGF}) is worth mentioning in this respect. Neurtrophin-3 (NT3), another member of the NGF-family of proteins, enhances migration of premyelinating Schwann cells via Dbs/MCF2L [36], possibly implicating nociception in OA. Interestingly, antibodies generated against NGF or its receptor have been used successfully to treat OA patients and effectively reduced their pain [37]. The fact that \textit{NGF} was not identified previously by comparing healthy with OA affected cartilage [7,8] suggests that \textit{NGF} may be more specific for the “late” OA process. Alternatively, selection of druggable targets from early-responsive genes that start changing showed 1.4-fold lower expression (Table S4) in accordance with a previous study by Raine \textit{et al.} showing increased expression of \textit{HBPI} in OA affected cartilage [35]. Given that \textit{HBPI} resides in the 7q22 gene cluster [24] results mark this gene as most likely candidate for further functional follow-up investigations.

Although \textit{MCF2L} (MCF.2 cell line derived transforming sequence-like), a gene previously identified in GWA as an OA susceptibility gene [22], was not well-detected in the microarray analysis, the significant increased expression of neuronal growth factor (\textit{NGF}) is worth mentioning in this respect. Neurtrophin-3 (NT3), another member of the NGF-family of proteins, enhances migration of premyelinating Schwann cells via Dbs/MCF2L [36], possibly implicating nociception in OA. Interestingly, antibodies generated against NGF or its receptor have been used successfully to treat OA patients and effectively reduced their pain [37]. The fact that \textit{NGF} was not identified previously by comparing healthy with OA affected cartilage [7,8] suggests that \textit{NGF} may be more specific for the “late” OA process. Alternatively, selection of druggable targets from early-responsive genes that start changing showed 1.4-fold lower expression (Table S4) in accordance with a previous study by Raine \textit{et al.} showing increased expression of \textit{HBPI} in OA affected cartilage [35]. Given that \textit{HBPI} resides in the 7q22 gene cluster [24] results mark this gene as most likely candidate for further functional follow-up investigations.

Figure 2. Representative slides of immunohistochemical staining. A) H&E staining. B) Toluidine blue staining. C) SERPINE1. D) CD55 (magnification 20x; insets show larger overview at magnification 4x; white scale bars indicate 50 μm and 200 μm, respectively). The left panels show preserved cartilage area (P) and the right panels show the OA affected cartilage area (OA). doi:10.1371/journal.pone.0103056.g002
before damage is irreversible could be more eligible to effectively
slow-down or stop the OA process.

The sample collection is performed by well-trained lab
personnel, however, we cannot exclude the possibility of minor
contamination with bone tissue. In this respect, it is of note that
several cartilage-specific genes (e.g. decorin or DCN, collagen type
2 A1 (COL2A1), cartilage intermediate layer protein (CILP), and
cartilage oligomeric matrix protein (COMP) were amongst the 100
genes with highest levels of expression in the dataset while no
bone-specific genes (e.g. COL1A1, COL1A2, TNFRSF11B, and
bone sialoprotein II or IBSP) were identified here.

In conclusion, our results add to the insight into the ongoing
pathological processes in OA cartilage by the identification of
different gene expression patterns depending on OA severity as
determined by Mankin score. This large scale analysis of joint-
matched OA affected and preserved cartilage seems to hint at
relatively consistent changes in gene expression during OA
development. We think research and development of OA
treatment could benefit by focusing on these similarities in gene
expression changes and/or pathways.

**Supporting Information**

**Figure S1** Typical example of hip (A) and knee (B) joint
with areas of macroscopically preserved (arrow head) and
OA affected cartilage (arrow; white scale bars indicate 500 mm).
Insets show detail of preserved (right) and
OA affected area (left), in A separated by a dashed line (scale bar
inset in B: 250 mm).

**Figure S2** Individual box plots per status for genes
validated by RT-qPCR.

**Figure S3** Relative changes in gene expression levels in
preserved and OA affected cartilage relative to healthy

### Table 5. Genes identified in robust genome wide approaches with fold-changes and P-values for OA versus preserved cartilage (OA vs P).

| Gene   | Ref | Joint published | OA vs P |
|--------|-----|-----------------|---------|
| ASTN2  | [28] | Hip&Knee | – | – |
| BCAP29 | [24] | Knee | 1.1 | 1.7×10⁻² |
| BTN2   | [26] | Knee | – | – |
| C6orf130 | [27] | Hip&Knee | 0.88 | 1.6×10⁻³ |
| CDC5L  | [28] | Hip&Knee | – | – |
| CHST11 | [28] | Hip&Knee | – | – |
| CPG5   | [24] | Knee | 0.98 | 2.1×10⁻¹ |
| COL11A1| [27] | Hip&Knee | 0.94 | 4.5×10⁻¹ |
| DOT1L  | [20] | Hip | – | – |
| DUS4L  | [24] | Knee | – | – |
| DWDA   | [25] | Knee | – | – |
| FLI1P1 | [28] | Hip&Knee | – | – |
| FTO    | [28] | Hip&Knee | 1.0 | 8.5×10⁻¹ |
| GDF5   | [21] | Hip&Knee | 1.1 | 4.3×10⁻² |
| GLT8D1 | [28] | Hip&Knee | 1.0 | 3.0×10⁻¹ |
| GNL3   | [28] | Hip&Knee | 1.1 | 4.6×10⁻² |
| GPR22  | [24] | Knee | – | – |
| HBP1   | [24] | Knee | 1.1 | 2.0×10⁻³ |
| HLA-DQB1| [26] | Knee | – | – |
| KLHDC5 | [28] | Hip&Knee | 1.0 | 4.8×10⁻¹ |
| MFC2L  | [22] | Hip&Knee | – | – |
| MICAL3 | [27] | Hip&Knee | – | – |
| MCOA3  | [23] | Hip | 0.93 | 7.9×10⁻³ |
| PAPPA  | [28] | Hip&Knee | 2.1 | 1.1×10⁻⁶ |
| PRKAR2B| [24] | Knee | 1.0 | 9.9×10⁻¹ |
| PTH1H  | [28] | Hip&Knee | 1.4 | 1.8×10⁻³ |
| SEMP6  | [28] | Hip&Knee | 1.1 | 3.3×10⁻¹ |
| Supt3H | [28] | Hip&Knee | 1.0 | 6.1×10⁻¹ |
| TP63   | [28] | Hip&Knee | – | – |
| VEGF   | [29] | Hip | 1.0 | 4.5×10⁻¹ |

(Ref: reference, where indicated gene was published as OA susceptibility gene; Pval: nominal P-value; FC: fold change; –: not detected on microarray).
doi:10.1371/journal.pone.0103056.t005
cartilage for the 19 genes with at least 2-fold difference in the OA versus preserved analysis (note that the line does not imply continues changes given the fact that the healthy cartilage was derived from independent donors).

(Table S1 Characteristics of OA donors included in the microarray analyses (discovery) and in the replication and characteristics of the healthy donors included in the microarray analysis. (XLSX))

Table S2 Taqman probes used in the fluidigm RT-qPCR experiment. (XLSX)

Table S3 Genes significantly differently expressed between OA and preserved cartilage in microarray analysis of 33 paired OA affected and preserved samples (FC: fold change; Pval: P-value; highlighted in yellow the genes that are also significantly different in the healthy versus preserved cartilage comparison). (XLSX)

References

1. Goldring MB, Marcu KB (2009) Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 11: 224.
2. Loeser RF, Goldring SR, Scanzello CR, Goldring MB (2012) Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 64: 1697–1707.
3. Bos SD, Slagboom PE, Meulenbelt I (2008) New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol 20: 553–559.
4. Sandell LJ (2012) Etiology of osteoarthritis: genetics and synovial joint development. Nat Rev Rheumatol 8: 77–89.
5. Gonzalez A (2013) Osteoarthritis year 2013 in review: genetics and genomics. Osteoarthritis Cartilage 21: 1443–1451.
6. Aigner T, Funkel K, Saa J, Gebhardt PM, Haag J, et al. (2006) Large-scale gene expression profiling reveals major pathogenic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum 54: 3533–3544.
7. Xu Y, Barter MJ, Rankin KS, Rowan AD, et al. (2012) Identification of the pathogenic pathways in osteoarthritic hip cartilage: commonality and discord between hip and knee OA. Osteoarthritis Cartilage 20: 1029–1038.
8. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, et al. (2010) Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage 18: 581–592.
9. Geyer M, Grassel S, Straub RH, Schett G, Dünser R, et al. (2009) Differential transcript analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritic pathophysiology. Osteoarthritis Cartilage 17: 320–335.
10. Tsuritani K, Takeda J, Sakagami J, Ishii A, Eriksson T, et al. (2010) Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53: 523–537.
11. Sato T, Konomi K, Yamasaki S, Aratani S, Tsuchimochi K, et al. (2006) Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage and involved in osteoarthritis downstream of TGF-beta. Calcif Tissue Int 80: 47–57.
12. Sato T, Konomi K, Yamasaki S, Aratani S, Tsuchimochi K, et al. (2006) Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage. Arthritis Rheum 54: 808–817.
13. Goeman JJ, van de Greer SA, de KF, van Houwelingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 95–99.
14. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
15. Citri A, Pang ZP, Sudhof TC, Wernig M, Malenka RC (2012) Comprehensive qPCR profiling of gene expression in single neuronal cells. Nat Protoc 7: 118–127.
16. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
17. Bos SD, Boes J, Duinjivel FD, Raine EV, van Dalem WJ, et al. (2012) Increased type II deiodinase protein in OA-affected cartilage and alleviates imbalance of OA risk polymorphism rs223014 at DIO2 in human OA joint tissues. Ann Rheum Dis 71: 1254–1258.
18. Mankin HJ, Dorfman H, Lippello L, Zarins A (1971) Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritis human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53: 523–537.
19. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
20. Schlaerzky D, Franceschina A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561-D566.
21. Castano Betancourt MC, Caiotto F, Kerkhof HJ, Cornelis FM, Doherty SA, et al. (2012) Genome-wide association and functional studies identify the DOR1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci U S A 109: 8218–8223.
22. Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, et al. (2008) A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet 17: 1497–1504.
23. Day-Williams AG, Southam I, Panoussopoulos E, Rayner NW, Eko T, et al. (2011) A Variant in MCF2L Is Associated with Osteoarthritis. Am J Hum Genet 89: 446–450.
24. Evangelou E, Kerkhof HJ, Styrkarsdottir U, Ntzani EE, Bos SD, et al. (2013) A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Ann Rheum Dis, doi: 10.1136/annrheumdis-2012–203114.
25. Kerkhof HJ, Lories RJ, Meulenbelt I, Jensenstorff I, Valdes AM, et al. (2010) A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum 62: 499–510.
26. Miyamoto Y, Shi D, Nakajima M, Ozaki K, Sudo A, et al. (2008) Common variants in DVWA on chromosome 3q24.3 are associated with susceptibility to knee osteoarthritis. Nat Genet 40: 994–998.
27. Nakajima M, Takahashi A, Kou I, Rodriguez-Fontenla C, Gomez-Reino JJ, et al. (2010) New sequence variants in HLA class II/III region associated with susceptibility to knee osteoarthritis identified by genome-wide association study. PLoS One 5: e9723.
28. Panoussopoulos K, Southam I, Elliott KS, Wrayner N, Zhai G, et al. (2011) Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis 70: 864–867.
29. Zeggini E, Panoussopoulos K, Southam I, Rayner NW, Day-Williams AG, et al. (2012) Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet 380: 815–823.
30. Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, et al. (2013) Assessment of osteoarthritis candidate genes in a meta-analysis of 9 genome-wide association studies. Arthritis Rheum 66: 949–949.
31. Ramos YF, Bos SD, van der Breggen R, Kloppenburg M, Ye K, et al. (2014) A gain of function mutation in TNFRSF11B encoding osteoprotegerin causes osteoarthritis with chondrocalcinosis. Ann Rheum Dis, doi: 10.1136/annrheumdis-2013–205149.
32. Barter MJ, Young DA (2013) Epigenetic mechanisms and non-coding RNAs in osteoarthritis. Curr Rheumatol Rep, doi: 10.1007/s11907-013-0319-4.

Table S4 Genes significantly differently expressed between preserved and healthy cartilage (FC: fold change; Pval: P-value). (XLSX)

Table S5 Results of the validation of the genes with at least 2-fold significant differential expression between OA affected and preserved cartilage in the microarray analyses (Dir: direction of effects; FC: fold change; Pval: P-value). (XLSX)

Acknowledgments

We thank I. Briaire-de Bruin for expert technical assistance with the immunohistochemistry.

Author Contributions

Conceived and designed the experiments: YR PS SB IM. Performed the experiments: YR WH NB LN SB. Analyzed the data: YR WH SB JG JB IM. Contributed reagents/materials/analysis tools: YR WH NB RB NL JCK JG RN SB. Wrote the paper: YR WH SB IM. Critical reviewing and approval of the manuscript: YR WH SB IM.

Large Scale Gene Expression Profiling of OA Cartilage.
33. Styrkarsdottir U, Thorleifsson G, Helgadottir HT, Bonner N, Metrustry S, et al. (2014) Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31. Nat Genet 46: 498–502.
34. Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, et al. (2013) Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthritis Res Ther 15: R190; doi: 10.1186/ar4380.
35. Raine EV, Wreglesworth N, Dodd AW, Reynard LN, Loughlin J (2012) Gene expression analysis reveals HBPI as a key target for the osteoarthritis susceptibility locus that maps to chromosome 7q22. Ann Rheum Dis 71: 2020–2027.
36. Yamauchi J, Chan JR, Miyamoto Y, Tsujimoto G, Shooter EM (2005) The neurotrophin-3 receptor TrkC directly phosphorylates and activates the nucleotide exchange factor Dbs to enhance Schwann cell migration. Proc Natl Acad Sci U S A 102: 5190–5203.
37. Seidel MF, Lane NE (2012) Control of arthritis pain with anti-nerve-growth factor: risk and benefit. Curr Rheumatol Rep 14: 583–588.